Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

γ -Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?

Toyn JH, Rowley A, Matsuoka Y, Tomita T, Imbimbo BP.

Int J Alzheimers Dis. 2013;2013:849128. doi: 10.1155/2013/849128. Epub 2013 Apr 18. No abstract available.

2.

CD147, a gamma-secretase associated protein is upregulated in Alzheimer's disease brain and its cellular trafficking is affected by presenilin-2.

Nahalkova J, Volkmann I, Aoki M, Winblad B, Bogdanovic N, Tjernberg LO, Behbahani H.

Neurochem Int. 2010 Jan;56(1):67-76. doi: 10.1016/j.neuint.2009.09.003. Epub 2009 Sep 12.

PMID:
19751784
3.

Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.

Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M.

J Neurochem. 2005 Sep;94(5):1189-201. Epub 2005 Jun 30.

4.
5.

The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease.

Tomita T, Iwatsubo T.

Drug News Perspect. 2004 Jun;17(5):321-5. Review.

PMID:
15334182
6.

At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism.

Tomita T.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):295-300. Epub 2007 Nov 24. Review.

PMID:
18038124
7.

Regulation of gamma-secretase activity in Alzheimer's disease.

Zhou S, Zhou H, Walian PJ, Jap BK.

Biochemistry. 2007 Mar 13;46(10):2553-63. Epub 2007 Feb 14.

PMID:
17298085
8.
9.

In vitro gamma-secretase cleavage of the Alzheimer's amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc.

Hoke DE, Tan JL, Ilaya NT, Culvenor JG, Smith SJ, White AR, Masters CL, Evin GM.

FEBS J. 2005 Nov;272(21):5544-57.

10.

γ-Secretase as a target for Alzheimer's disease.

Wolfe MS.

Adv Pharmacol. 2012;64:127-53. doi: 10.1016/B978-0-12-394816-8.00004-0. Review.

PMID:
22840746
11.

Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease.

Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S.

Curr Neuropharmacol. 2011 Dec;9(4):598-622. doi: 10.2174/157015911798376352.

12.
13.

The Alzheimer's disease-associated gamma-secretase complex: functional domains in the presenilin 1 protein.

Laudon H, Winblad B, Näslund J.

Physiol Behav. 2007 Sep 10;92(1-2):115-20. Epub 2007 May 21. Review.

PMID:
17588625
14.

Familial Alzheimer's disease presenilin 1 mutation M146V increases gamma secretase cutting of p75NTR in vitro.

Hatchett CS, Tyler S, Armstrong D, Dawbarn D, Allen SJ.

Brain Res. 2007 May 25;1147:248-55. Epub 2007 Feb 7.

PMID:
17349981
15.

γ-secretase substrates and their implications for drug development in Alzheimer's disease.

Lleó A, Saura CA.

Curr Top Med Chem. 2011;11(12):1513-27. Review.

PMID:
21510835
16.

Gamma-secretase inhibitors and Alzheimer's disease.

Roberts SB.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1579-88. Review.

PMID:
12453675
17.

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF.

Drugs R D. 2006;7(2):87-97. Review.

PMID:
16542055
18.

Amyloid metabolism and secretases in Alzheimer's disease.

Xia W.

Curr Neurol Neurosci Rep. 2001 Sep;1(5):422-7. Review.

PMID:
11898552
19.

gamma-Secretase as a target for drug intervention in Alzheimer's disease.

Harrison T, Churcher I, Beher D.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):709-19. Review.

PMID:
15503873
20.

Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.

Pollack SJ, Lewis H.

Curr Opin Investig Drugs. 2005 Jan;6(1):35-47. Review.

PMID:
15675602

Supplemental Content

Support Center